BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34520614)

  • 1. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
    Santos M; Protopopescu C; Delarocque-Astagneau E; Bourlière M; Petrov-Sanchez V; Di Beo V; Larrey D; Baudoin M; Dorival C; Bureau M; Fontaine H; Carrat F; Marcellin F; Pol S; Carrieri P;
    Liver Int; 2022 Jan; 42(1):38-49. PubMed ID: 34520614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
    Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
    Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER).
    Barré T; Ramier C; Di Beo V; Carrat F; Fontaine H; Marcellin F; Carrieri P; Pol S; Protopopescu C;
    Liver Int; 2021 Jul; 41(7):1694-1698. PubMed ID: 33993651
    [No Abstract]   [Full Text] [Related]  

  • 4. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
    Barré T; Nishimwe ML; Protopopescu C; Marcellin F; Carrat F; Dorival C; Delarocque-Astagneau E; Larrey D; Bourlière M; Petrov-Sanchez V; Simony M; Pol S; Fontaine H; Carrieri P;
    J Viral Hepat; 2020 Dec; 27(12):1473-1483. PubMed ID: 32810343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
    Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP;
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.
    Lim JK; Tate JP; Fultz SL; Goulet JL; Conigliaro J; Bryant KJ; Gordon AJ; Gibert C; Rimland D; Goetz MB; Klein MB; Fiellin DA; Justice AC; Lo Re V
    Clin Infect Dis; 2014 May; 58(10):1449-58. PubMed ID: 24569533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
    Bischoff J; Boesecke C; Ingiliz P; Berger F; Simon KG; Lutz T; Schewe CK; Schulze Zur Wiesch J; Hueppe D; Christensen S; Mauss S; Baumgarten A; Rockstroh JK;
    J Clin Gastroenterol; 2020 Feb; 54(2):192-199. PubMed ID: 30789853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
    Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
    Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
    Lam L; Fontaine H; Lapidus N; Bellet J; Lusivika-Nzinga C; Nicol J; Dorival C; Cagnot C; Hejblum G; Pol S; Bourlière M; Carrat F;
    J Viral Hepat; 2023 Mar; 30(3):232-241. PubMed ID: 36529681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
    Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F;
    BMC Infect Dis; 2010 Oct; 10():303. PubMed ID: 20969743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014.
    Sanna A; Le Strat Y; Roudot-Thoraval F; Deuffic Burban S; Carrieri P; Delarocque-Astagneau E; Larsen C
    Euro Surveill; 2017 Jul; 22(30):. PubMed ID: 28797326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
    Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
    BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.